FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) has been awarded a Phase II Small Business Innovative Research (SBIR) Grant from the National Institute for Diabetes and Digestive Kidney Diseases (NIDDK), a division of the National Institutes of Health. The Phase II award, which will provide approximately $900,000 over two years, will fund the continuation of Unigene’s proprietary discovery program to identify novel therapeutic peptide hormones.
